AANS/CNS SECTION
ON TUMORS

Collaborative Opportunities with the Blood-Brain Barrier Consortium for Diagnostic and Therapeutic Clinical Trials

The Oregon Health & Science University (OHSU) Blood-Brain Barrier (BBB) and Neuro-Oncology Program is pleased to present an ancillary session during the Society for Neuro-Oncology Annual Meeting titled “Collaborative Opportunities with the Blood-Brain Barrier Consortium for Diagnostic and Therapeutic Clinical Trials.” This session will present information on current and potential opportunities for collaboration on ongoing multicenter diagnostic and therapeutic clinical trials led by the BBB Consortium.

Discussion will be led by study investigators and include presentations on steady state neuroimaging, immunotherapy for brain tumors, antibody drug conjugate drug therapy, maintenance immunotherapy for primary central nervous system lymphoma, and the use of thiols for hearing protection particularly in pediatric patients with medulloblastoma.

This unique opportunity provides a stellar platform for increased exposure of these multicenter trials, as well as potential for input and participation from leaders in the field of neuro-oncology.

Registration and dinner are complimentary. Individuals who are not registered for the SNO Annual Meeting are welcome to attend; however, SNO registration is required to attend other sessions.

For more information, visit www.ohsu.edu/bbbmidannual or contact Emily Youngers at hochhalt@ohsu.edu or 503-494-5696.

The 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology will be held on November 16-19, 2017 at the Marriott Marquis in San Franciso, California.

This year's meeting will highlight a number of the 10 Blue Ribbon Panel Recommendations related to the “Cancer Moonshots”  program. Dr. WK Alfred Yung, a member of the Blue Ribbon Panel, will present an introduction to the Moonshot program and three prominent keynote speakers will offer presentations related to the specific recommendations. Scientific Program Chairs are: Manish Aghi, MD, Phd, Frank Furnari, PhD, and Vinay Puduvalli, MD.

In keeping with the main meeting theme, the Education Day will focus on two of the Cancer Moonshot Blue Ribbon Panel recommendations: “Developing Ways to Overcome Resistance” and “Minimizing Cancer Treatments Debilitating Side Effects.” Concurrent tracks in both basic science and applied neuro-oncology will offer a comprehensive look at these two recommendations. Education Day Chairs are: Khalid Shah, PhD, Albert Kim, MD, PhD, Susan Bell, MS, APN, and Robert Cavaliere, MD.

The 2017 SNO-SCIDOT Conference on Therapeutic Delivery to the CNS will be held on November 15 - 16th, also at the Marriott Marquis. This conference is jointly hosted by the Society for Neuro-Oncology (SNO) and the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT). Conference Chairs: Michael Vogelbaum, MD, PhD (SCIDOT), Manish Aghi, MD, PhD (SNO).

For more information, visit www.soc-neuro-onc.org.